Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01359527
Recruitment Status :
Active, not recruiting
First Posted : May 24, 2011
Last Update Posted : December 13, 2017
Spokane Joint Replacement Center
Information provided by (Responsible Party):
David F. Scott, MD, Spokane Joint Replacement Center
This study compares the change (loss) of bone mineral density (BMD) that occurs in the proximal femur after hip resurfacing and total hip replacement.
Condition or disease
Device: Hip ResurfacingDevice: Total Hip Arthroplasty
This study compares the change (loss) of bone mineral density (BMD) that occurs in the proximal femur after hip resurfacing and total hip replacement. The goal is to evaluate the bone loss in the proximal femur resulting from hip resurfacing surgery and to compare this to the bone loss in the proximal femur resulting from total hip arthroplasty.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult patients undergoing hip replacement or resurfacing for osteoarthritis
Age of at least 20 years
Elective Total Hip Arthroplasty / Resurfacing
Signed Informed Consent
Breast-feeding, pregnancy, or women of child-bearing potential without documentation of a negative pregnancy test and not utilizing contraception
Patients with a history of having taken or currently taking PTH, fluoride therapy or strontium ranelate or patients taking other chronic medications that in the Investigator's opinion are known to affect bone mineral density in a substantial way
Patients with severe medical condition(s) that in the view of the Investigator prohibits participation in the study
Use of any other investigational agent in the last 30 days